CLIA Laboratory Director (high-complexity) AP/CP Pathologist
Resume:
Angela Aimee Steinhardt
Milton, MA 02186
Telephone: 765-***-****
E-Mail: adwxac@r.postjobfree.com
Licensure and
Certification
Louisiana Board of Medicine
Medicine and Surgery License Number: 331162
Issue Date: 5/24/2022; Expiration Date: 5/31/2024; Current Status: Active
LA Controlled Substance License Number: CDS.064014-MD Issued: 10/07/2022
Expiration Date: 10/07/2023
Current Status: Active
DC Board of Medicine
Medicine and Surgery License Number: MD210002104 Issue Date: 03/08/2022; Expiration Date: 12/31/2024
DC Controlled Substance License Number: CS210126331 Expiration Date: 12/31/2024
Current Status: Active
Massachusetts Board of Registration in Medicine
Medical License, Number: 242648
Issue Date: 05/19/2010
Expiration Date: 05/30/2025
Current Status: Active
Massachusetts Controlled Substance Registration Number: MS0908256A Issue Date: 04/04/2013
Expiration Date: 06/02/2025
Address of Registration: 85 West St, Walpole, MA 02081-1844 DEA Registration Number: FS3789647; XS3789647
Schedules: 2, 2N, 3, 3N, 4, 5
Business Activity: Practitioner-DW/275
Issue Date: 02/13/2019
Expiration Date: 02/28/2025
Address of Registration: 85 West St, Walpole, MA 02081-1844 Education and
Training
Medical Board of California
Medical License, Number: A112942
Issue Date: June 25, 2010
Expiration Date: May 31, 2024
Current Status: Active
Indiana Board of Pharmacy
Pharmacist License, Number: 26020928A
Issue Date: 08/14/2002
Expiration Date: 06/30/2024
Current Status: Active
Suboxone Certification, American Academy of Addiction Psychiatry Office Based Buprenorphine Treatment
June 6, 2013
American Board of Pathology
Board Certified in AP/CP Pathology
Examination Date: 05/22/2017
American Board of Pathology Diplomate, 8/7/2017
American Red Cross
Adult/Child/Infant CPR/First Aid/AED Online
Issued: 04/05/2023
Expires: 04/05/2025
Massachusetts Cannabis Control Commission
Medical Use of Marijuana Online System
Registered Medical Provider
Registration Number: D16821
Start Date: 03/16/21
Purdue University School of Pharmacy
West Lafayette, IN 47907
Bachelor of Science: May 11, 2002
Graduation with Distinction (Top 10% of Class)
Cumulative GPA: 3.74/4.00
Class Rank: 5/60
August 2003—June 2007
Indiana University School of Medicine
Indiana University-Purdue University-Indianapolis Medical Center Indianapolis, IN 46202
Doctor of Medicine: June 30, 2007
July 2007-June 2008
Pathology GI Cancer Research Fellowship
Johns Hopkins University School of Medicine
Department of Gastrointestinal Pathology
1550 Orleans St, CRB2-316
Baltimore, MD 21287
July 1, 2008-June 30, 2010
AP/CP Pathology Residency
David Geffen School of Medicine @ UCLA
UCLA Medical Center
10833 Le Conte Ave
Los Angeles, CA 90095
July 1, 2010-June 30, 2012
AP/CP Pathology Residency
Harvard Medical School
Beth Israel Deaconess Medical Center
330 Brookline Ave
Boston, MA 02115
July 1, 2012-June 30, 2013
General Surgical Pathology Fellowship
Subspecialty Focus: Genitourinary Pathology
Harvard Medical School
Beth Israel Deaconess Medical Center
330 Brookline Ave
Boston, MA 02115
Harvard University Extension School
Cambridge, MA
Masters of Liberal Arts, Finance
Graduation Date: May 26, 2016
Recent
Work Experience
April 22, 2021-Present
May 2021-Present
Assurance Scientific
2 Perimeter Park South
Birmingham, AL 35243
Laboratory Director Consultant (High Complexity)
I oversee operations in laboratories offering wound culture molecular PCR testing for podiatrist offices. I review QA/QC and validation studies, perform corrective action if needed, do proficiency testing, and prepare for inspections.
Leafwell MD
04/09/2021-Present
Medical Cannabis Certification Consultant
HIPAALINE LLC
9100 S DADELAND BLVD STE 1701
MIAMI FL 33156
Perform patient histories to determine if patients qualify for therapeutic cannabis in the state of Massachusetts, California, Louisiana and Washington DC.
March 12, 2021-December 2, 2022
DTPM
913 Airport Road W.
Fort Payne, AL 35968
Laboratory Director and Technical Supervisor (High Complexity) P: 256-***-****, ext 245
Oversee operations in a laboratory which does urine toxicology testing. I sign off on QA/QC studies, validation studies, review temperature charts, review proficiency testing results and prepare for inspections. October 26, 2020-June 16, 2023
Octapharma Plasma
752 Crescent St
Brockton, MA 02302
Licensed Physician Consultant
I review medical charts and donor reaction reports and help to train physician substitutes to do patient histories and physical exams. Review SOPs for changes and do competency assessments for technicians and physician substitutes. Center closed on May 19, 2023.
August 27, 2019-September 30, 2020
Thrive Earlier Detection Corp
138 Sidney St
Cambridge, MA 02139
Laboratory Director (High Complexity)
Oversee operations in a laboratory which does genetic testing for cancer biomarkers. I sign off on QA/QC studies, validation studies, review proficiency testing results and prepare for inspections. April 26, 2019-June 30, 2022; March 1, 2023-Present Commonwealth Diagnostics International, Inc
39 Norman St
Salem, MA 01970
Laboratory Director and Technical Supervisor (Moderate Complexity) Oversee operations in a laboratory which does IBSChek testing for Gastrointestinal (GI) bacterial overgrowth in patients with GI complaints. I sign off on QA/QC studies, validation studies, review proficiency testing results and prepare for inspections.
August 10,2017- Present
Path AI
120 Brookline Ave
Boston, MA 02215
Consultant Digital AI Research Pathologist
I’m a digital pathologist who reviews slides to correct heatmaps that differentiate tumor, stroma and normal areas of a tissue. I also perform corrections on heatmaps that differentiate different cell types (lymphocytes, cancer cells, stromal cells, fibroblasts, macrophages, plasma cells, endothelial cells). The work I do leads to the improvement of machine learning technology used to assist pathologists doing diagnostic and research work.
April 4, 2016—December 31, 2020
Aspenti Health
57 Commerce Way
Woburn, MA 01801
Laboratory Director (High complexity)
Oversee operations in a laboratory which does urine toxicology testing. I sign off on QA/QC studies, validation studies, review temperature charts, review proficiency testing results and prepare for inspections. November 11, 2013—July 31, 2019
Discovery Diagnostic Labs
186 Cedar Hill St
Marlborough, MA 01752
Laboratory Director (High Complexity)
Oversee operations in a laboratory which does urine toxicology testing. I sign off on QA/QC studies, validation studies, review temperature charts, review proficiency testing results and prepare for inspections. July 1, 2016--present
Anchor Medical and Wellness Group
85 West St
Walpole, MA 02081
Suboxone/Addiction Medicine Physician
This position involves the evaluation and treatment of patients with opioid dependence with Suboxone. I review their lab results and discuss them with every patient at each visit and provide medication counseling. If patients are struggling, I will try to get them treatment through an inpatient detox program or an intensive outpatient treatment program.
July 1, 2013—June 30, 2016
Bay State Medical Associates, PC
1717 Main St
Brockton, MA 02301
Suboxone Medication Counseling Physician
This position involves the evaluation and treatment of patients with opioid dependence with Suboxone. I review their lab results and discuss them with every patient at each visit and provide medication counseling. If patients are struggling, I will try to get them treatment through an inpatient detox program or an intensive outpatient treatment program.
July 30, 2013—March 1, 2014
Quest Diagnostics
3 Sterling Dr
Wallingford, CT 06492
Staff Pathologist (Monday-Friday)
I practiced as a general surgical pathologist reviewing histopathology and cytopathology cases from multiple tissue types (GYN, GI, GU, skin, blood smears, lung, thyroid). I communicated results to other physicians as well as prepare reports that describe the findings of biopsies and surgical resections. Oct 1, 2013—March 1, 2014
Quest Diagnostics
7 Germantown Rd
Danbury, CT 06810
Lab Director
Oct 1, 2013—March 1, 2014
Quest Diagnostics
2 Church St S Ste 115
New Haven, CT 06519
Lab Director
Oct 1, 2013—March 1, 2014
Quest Diagnostics
1008 N. Main St
Branford, CT 06405
Lab Director
At Quest, I also overseed the operations of 3 different laboratories that performed mainly hematology and chemistry testing. I sign off on QA/QC studies, validation studies, review temperature charts, review proficiency testing results and prepare for inspections.
Awards and Honors
2019 Top Doctor Award (AP/CP Pathology and Addiction Medicine) 2002 The National Dean’s List 25th Edition (2001-2002) 2002 The Honor Society of Phi Kappa Phi
2001 Omicron Delta Kappa National Leadership Society
• Secretary (2001-2002)
● Vice-President for Membership (2002)
2001 Purdue University Homecoming Queen Finalist
2001 The Rho Chi Society
2001 Joseph E. McSoley Pharmacy Scholarship Recipient 2001 National Scholars Honor Society
2001 Iota Sigma Pi National Chemistry Honor Society 2001 Psi Chi National Honor Society in Psychology
2001 National Society of Collegiate Scholars
2001 Beta Beta Beta National Biological Honor Society 2001 Alpha Epsilon Delta Pre-Medical Honor Society
• Co-Treasurer, Physician Shadowing Coordinator (2001) 2001 Alpha Sigma Lambda National Honor Society
• Vice-President (2001-2002)
2000 Helen Carney Scholarship Recipient
1998 Golden Key National Honor Society
1998 Phi Lambda Sigma Pharmacy Leadership Society
1996 Alpha Lambda Delta Freshman Honorary
1996 Phi Eta Sigma Freshman Honorary
1995-2002 Dean’s List
1995-2002 Semester Honors
Volunteer
Experience
Research
Experience
2005 Impact Christian Health Center Medical Student Volunteer 2001 The Rho Chi Society—March of Dimes Walk America 2001 Alpha Epsilon Delta--Lafayette Urban Ministry Volunteer 1999 Phi Lambda Sigma Ronald Mc Donald House Project 1998 Phi Lambda Sigma Community Recycling Project
1997 Kappa Epsilon Breast Cancer Awareness Project 1996 Alpha Lambda Delta—Soup Kitchen Volunteer
1996 American Red Cross Disaster Services Course 1995 Special Olympics Volunteer
May 2004—August 2004
Center for Paralysis Research
Purdue University
West Lafayette, IN 47907
Faculty Mentor: Richard Borgens,PhD
Project Title: Axonal sealing time in crush injuries vs. transaction injuries of the spinal cord
Brief Description: I placed 2 sections of guinea pig spinal cords with newly induced injuries—one section with transection injury and one section with crush injury in an isotonic solution with Fluoro-Ruby® dye for about 60 minutes. Then, I froze the sections with liquid nitrogen and made thin frozen sections (5 micrometer thick). From these sections, I could determine the distance the dye migrated through the axon (before the axon seals off) by counting the number of sections which contained the fluorescent dye. Examination of the sections containing the fluorescent dye was identified using a fluorescent microscope. Then, I divided the distance (# of thin sections containing dye x 5 micrometers/thin section) by duration of injury
(60 minutes) to get the axonal sealing time. Then, I compared the results for crush injuries vs. transaction injuries.
July 2007—June 2008
Department of Pathology
Johns Hopkins University School of Medicine
Baltimore, MD 21287
Faculty Mentor: Robert A. Anders, MD, PhD
Project 1 Title: Expression of Yes Associated Protein in Common Solid Tumors
In this study, YAP expression intensity in normal vs. neoplastic tissues of the colon, lung, ovary, and breast was investigated. Using patient tissue biopsies prepared into tissue microarrays and immunohistochemistry methods, YAP expression level was determined using a scoring system to measure intensity as negative, low, or high. Based on the results of the experiment, we concluded that YAP expression intensity is higher in neoplastic tissues than in normal tissues suggesting that a common oncogenic pathway involving YAP maybe involved in the process of tumorigenesis in different tissue types.
Project 2 Title: Investigation of a Novel Oncogenic Pathway in Hepatocellular Carcinoma
In this study, I investigate the amplification of the YAP gene in the genomic DNA of human hepatocellular carcinoma by using RT-PCR methods. YAP immunohistochemistry was used to compare YAP expression in normal liver cells vs. neoplastic cells of hepatocellular carcinoma. Results of experiments performed to date demonstrate amplification of YAP in the hepatocellular carcinoma cell lines vs. normal liver cells.
July 2009—August 2012
Department of Pathology
UCLA School of Medicine
Los Angeles, CA 90095
Faculty Mentor: Jonathan Braun, MD/PhD
Project Title: Progesterone Receptors A and B in Grade 1 Endometrial Adenocarcinoma and Complex Atypical Hyperplasia Predict Response to Progestin Therapy
Abstract for College of American Pathologists (CAP) Meeting 2010: Progesterone Receptors A and B in Grade 1 Endometrial Adenocarcinoma and Complex Atypical Hyperplasia Predict Response to Progestin Therapy Kristine Penner, MD, MPH1, Madhuri Wadehra, PhD2, Angela Steinhardt, MD, Claire Hogue2, Jonathan Braun, MD, PhD2, and Oliver Dorigo, MD, PhD1 1Departments of Obstetrics and Gynecology and, UCLA Medical Center, Los Angeles, California
2Departments of Pathology, UCLA Medical Center, Los Angeles, California Context: Ten percent of grade 1 endometrial adenocarcinomas (G1EACs) and complex atypical hyperplasias (CAHs) occur in patients younger than age 40. Progestin therapy is an option to preserve fertility, but no biologic markers that predict response are known. We investigated whether progesterone receptor isoforms A
(PRA) and B (PRB) at initial endometrial biopsy or first follow-up biopsy post- progestin therapy might predict treatment response. Design: We retrospectively identified premenopausal patients with CAH or G1EAC who had undergone progestin therapy for more than 8 weeks and for whom there was outcome data and available specimens pretreatment and within the first 9 months post-treatment. Immunohistochemical staining for PRA and PRB was performed on all tissues, tumors, and stroma. Results were evaluated using a histologic scoring system.
Results: We identified 38 subjects (median age, 36 years; age range, 23 to 48 years) who had an initial pathology of G1EAC (35%) or CAH (65%). Of these subjects, 50% had documented resolution to normal histopathology (median time, 7 months). Levels of both PRA and PRB were greater pretreatment versus post-treatment (P < .05); pretreatment expression of both isoforms was greater in tumor versus stroma (P <
.01); at first follow-up, there was no difference in expression between tumor tissue and stroma for either isoform; and a higher proportion of PRA (>0.6) to total PR in the initial specimen correlated with a higher likelihood of disease resolution (P = .04). Conclusions: The ratio of PRA and PRB for young patients with CAH or G1EAC at initial diagnostic biopsy may be a useful guide to individual likelihood of resolution of G1EAC or CAH with progestin therapy.
Abstract for United States and Canadian Academy of Pathology
(USCAP) Meeting 2011:
Progesterone Receptors A and B, pAkt, and p4EBP1 Expression Patterns in Grade 1 Endometrial Adenocarcinoma(G1EAC) and Complex Atypical Hyperplasia(CAH) and Prediction of Response to Progestin Therapy
Kristine Penner, Madhuri Wadehra, Angela Steinhardt, Claire Hogue, Ilana Cass, Christine Walsh, Christine Holschneider, Jonathan Braun and Oliver Dorigo 1Department of Obstetrics and Gynecology and Department of Pathology, UCLA Medical Center, Los Angeles, CA, United States; 2Olive View-UCLA Medical Center, Los Angeles, CA, United States and 3Cedars Sinai Medical Center, Los Angeles, CA, United States.
Background: Progestin therapy is a treatment option for CAH and G1EAC in women who desire fertility preservation. No markers that reliably predict response to treatment have been identified. Progesterone receptor status and activation of the pAkt/PTEN pathway have each been hypothesized to influence the effectiveness of progestin treatment. Progesterone receptor B(PRB)activation is known to alter the activity of this pathway. We investigated whether expression of progesterone receptor A(PRA) and B(PRB) as well as markers in the pAkt/PTEN pathway (pAkt and p4EBP1) change in response to progestin therapy and if any of these markers could be used to predict therapeutic response.
Design: Premenopausal patients with CAH or G1EAC who underwent progestin therapy for at least 8 weeks between 1998-2007 were retrospectively identified from three institutions. Patients had an initial diagnostic endometrial biopsy and a follow-up biopsy during the first nine months of treatment. Immunohistochemical (IHC) staining for PRA, PRB, pAkt and p4EBP1 was performed on all tissue. The H score system was used by a pathologist to quantify the IHC staining. H score>50 is considered positive with 50-100 weakly positive, 100-200 moderately positive, and 200-300 strongly positive. Tumor tissue was scored separately from stroma. Results: 38 subjects were identified with a median age of 36 years (range 23- 48).Moderate staining (H score >100) for PRA, PRB and pAkt was seen in 79%, 84%,and 62% of initial biopsies, respectively. Expression levels of all markers (PRA, PRB, pAkt, p4EBP1) were greater in the initial biopsy than after treatment
(p<0.05).Strong(H score >200) expression of PRB in the initial biopsy was significantly associated with resolution(83% vs. 44% resolution, p=.035). Laboratory Skills
Research
Publications and
Poster
Presentations
Organization/Club
Memberships
Conclusions: Our data suggests that progestin therapy appears to reduce expression of PRA, PRB, pAkt, and p4EBP1 in CAH and G1EAC, and hence, may influence activation of the pAkt/PTEN pathway. Strong PRB expression in both the initial and first follow-up biopsies with CAH or Grade 1 EA has the potential to predict response to progestin treatment. Staining for PRB in a patient's initial diagnostic biopsy therefore may provide additional information to assist in counseling patients regarding their individual likelihood of resolution of G1EAC and CAH with progestin therapy.
Preparing and splitting cell cultures, performing RT-PCR, pipetting, electrophoresis, immunohistochemistry staining techniques, handling laboratory mice, maintaining a laboratory journal, scientific writing Steinhardt AA, Gayyed MF, Klein AP, Dong J, Maitra A, Pan D, Montgomery EA, Anders RA. Expression of the Yes Associated Protein in Common Solid Tumors. Human Pathology. 39 (11):1582-1589.
Penner K, Wadehra M, Holschneider C, Cass I, Walsh I, Steinhardt A, Hogue C, Braun J, Dorigo O. Progesterone Receptor A and B Expression in Grade 1 Endometrial Adenocarcinoma and Complex Atypical Hyperplasia Predicts Response to Progestin Therapy. Oral Plenary Presentation: 39th annual meeting of the Western Association of Gynecologic Oncologists, Santa Barbara, CA, June 2010.
Penner K, Wadhuri M, Steinhardt A, Hogue C, Braun J, Dorigo O. Progesterone Receptors A and B in Grade 1 Endometrial Adenocarcinoma and Complex Atypical Hyperplasia Predict Response to Progestin Therapy.
(2010) Abstracts and Case Studies From the College of American Pathologists 2010 Annual Meeting. Archives of Pathology & Laboratory Medicine: Vol. 134, No. 9, pp. 1283-1396, September 2010. Penner K, Wadhuri M, Steinhardt A, Hogue C, Cass I, Walsh C, Holschneider C, Braun J, Dorigo O. Progesterone Receptors A and B, pAkt, and p4EBP1 Expression Patterns in Grade 1 Endometrial Adenocarcinoma(G1EAC) and Complex Atypical Hyperplasia(CAH) and Prediction of Response to Progestin Therapy (2011). United States and Canadian Academy of Pathology 2011 Annual Meeting. Laboratory Investigation 91, 263A, February 2011.
Penner K, Wadehra M, Steinhardt A, Hogue C, Cass I, Holschneider C, Walsh I, Braun J, Dorigo O. Expression of progesterone receptor and p4EBP1 as molecular predictors of response to progestin treatment in endometrial adenocarcinoma and complex atypical hyperplasia. Poster Presentation: 102nd annual meeting of the American Association for Cancer Research, Orlando, FL, April 2011.
Petrie M, Lynch K, Wu A, Steinhardt A, Horowitz G. Prescription Compliance or Illicit Designer Drug Abuse? Clinical Chemistry 58:12-201*-****-**** Harvard Kendo Club
2011-2016 Harvard Ballroom Dance Team
2011-2016 Harvard Extension Business Society
2010-present Harvard Club of Boston
2010-present College of American Pathologists (CAP) 2010-present Massachusetts Medical Society
2009-present United States and Canadian Academy of Pathology 2008-2010 Los Angeles Society of Pathologists
2003-2007 American Medical Student Association
2003-present Purdue University Alumni Association
2003-2007 American College of Physicians—
American Society of Internal Medicine
2003-present American Medical Association
2002-2003 Indiana Pharmacists Alliance
2001-2002 Caduceus Club for Pre-Medical Students
1999 Psychology Club--Crisis Center Volunteer
1997-2000 Kappa Epsilon Pharmaceutical Sorority
References
Amy Pearsall, MD
Medical Director, Anchor Medical and Wellness Group 85 West St
Walpole, MA 02081-1844
Phone: 646-***-****
Debra Leary
Operational Manager/Lab Supervisor
Anchor Medical and Wellness Group
85 West St
Walpole, MA 02081-1844
Deborah Sumner
President at Quality Systems and Compliance
100 Cummings Center
Suite 233C
Beverly, Massachusetts, USA 01915
Contact this candidate